6 Undervalued Pharmaceuticals Stocks for Wednesday, August 09
Discover the top 6 undervalued Pharmaceuticals stocks for Wednesday, August 09 based on AAII’s Stock Grades.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Commentary & Analysis
6 Undervalued Pharmaceuticals Stocks for Tuesday, June 27
Discover the top 6 undervalued Pharmaceuticals stocks for Tuesday, June 27 based on AAII’s Stock Grades.Jack Gilleland
Is TherapeuticsMD Inc (TXMD) Stock a Good Investment?
Learn more about TherapeuticsMD Inc's (TXMD) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Pharmaceuticals stock meets your investment needs.Zach Banning
Financial Summary
| Share Statistics | TXMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $23.7 | $569.9 | 11% |
|
| Shares Out (Mil) | 11.6 | 44.8 | 23% |
|
| Institutional Ownership | 91.4% | 84.6% | 60% |
|
| Float (Mil) | 9.5 | 45.1 | 19% |
|
| Beta | 0.60 | 0.67 | 34% |
|
| Avg Daily Volume (000s) | 21 | 294 | 21% |
|
| Price Change (52-week) |
76.7% | 65.2% | 88% |
|
| Growth | TXMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (45.9%) | 6.7% | 0% |
|
| Net Income (5yr) | 68.2% | (2.0%) | 97% |
|
| EPS (5yr) | 72.5% | 14.9% | 98 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.0% | (14.9%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TXMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $230 | 4% |
|
| Net Income (TTM) (Mil) | $0 | ($11) | 39% |
|
| EPS (TTM) | $0.015 | ($0.600) | 40% |
|
| Operating Cash Flow (TTM) (Mil) | $3 | ($6) | 34% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $5 | $7 | 24% |
|
| Enterprise Value (Q1) (Mil) | $23 | $493 | 11% |
|
| Valuation | TXMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.88 | 2.89 | 19% |
|
| P/E | 292.9 | 20.6 | 98% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 4.1 | 1.1 | 84% |
|
| Ratios | TXMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 65.9% | 96% |
|
| Net Margin | 5.3% | (0.2%) | 49% |
|
| ROA | 0.5% | (25.5%) | 42% |
|
| ROE | 0.7% | (21.4%) | 36% |
|
| Liabilities to Assets | 28.2% | 35.5% | 20% |
|
| F-Score | 8 | 3 | 94% |
|
TherapeuticsMD, Inc. did not pass any screens on 7/30/2026.
